Steve Jobs' son says he can help end cancer deaths - and he's raising millions to do it [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
diseases within his lifetime - and plans to spend hundreds of millions of dollars to back that belief. Jobs' venture capital firm, Yosemite, has raised more than $200 million for its second fund and hopes to raise $150 million more, Forbes reported Friday. The fund is backed by several major investors, including biotech giant Amgen, Memorial Sloan Kettering Cancer Center, MIT and venture capitalist John Doerr. After the recent funding round, Yosemite now manages more than $1 billion in assets, including money it oversees for hospitals, endowments and foundations, Forbes reported. "We think it's going to go from a death sentence to just a chronic lifelong disease," Jobs, 34, told Forbes. "I think it's doable in the timeframe of my lifetime for most cancers." Reed Jobs was 12 years old when his father was diagnosed with pancreatic cancer, one of the deadliest forms of the disease. Eight years later, in 2011, his father died at age 56. As a teenager, Reed Jobs worked in cancer
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) was given a new $400.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.MarketBeat
- AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTSPR Newswire
- Amgen Set to Report Q4 Earnings: What Investors Should Know [Yahoo! Finance]Yahoo! Finance
- TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026 [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 1/30/26 - Form 8-K
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- AMGN's page on the SEC website